Hologic, Inc. (NASDAQ:HOLX) Shares Bought by TD Private Client Wealth LLC

TD Private Client Wealth LLC grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 47.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 7,115 shares of the medical equipment provider’s stock after buying an additional 2,290 shares during the quarter. TD Private Client Wealth LLC’s holdings in Hologic were worth $513,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. First Horizon Advisors Inc. boosted its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the last quarter. Brooklyn Investment Group raised its holdings in shares of Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 145 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC grew its holdings in shares of Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 169 shares during the period. Finally, Loomis Sayles & Co. L P increased its position in Hologic by 29.3% during the third quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 183 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HOLX has been the subject of several analyst reports. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Citigroup reduced their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Jefferies Financial Group began coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Finally, Stephens restated an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Price Performance

Hologic stock opened at $61.89 on Tuesday. The firm has a market cap of $13.89 billion, a PE ratio of 19.52, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company’s 50 day moving average is $65.89 and its two-hundred day moving average is $73.81. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.